Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of < 3/40.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.

Original languageEnglish (US)
Pages (from-to)146-154
Number of pages9
JournalBone Marrow Transplantation
Volume53
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Autografts
Stem Cell Transplantation
HLA-DR Antigens
Natural Killer Cells
Lymphoma
Survival
Non-Hodgkin's Lymphoma
Confidence Intervals
Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Blood Component Removal
Lymphocyte Count
Multivariate Analysis
Survival Rate

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{e4655ff637734e2f8156d5a1b92e6685,
title = "Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation",
abstract = "The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of < 3/40.29 experienced superior OS (5-year OS rates of 84{\%} (95{\%} confidence interval (CI), 72-91{\%}) vs 48{\%} (95{\%} CI, 34-62{\%}), P<0.0002, respectively) and PFS (5-year PFS rates of 59{\%} (95{\%} CI, 47-71{\%}) vs 32{\%} (95{\%} CI, 20-48{\%}), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95{\%} CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95{\%} CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.",
author = "A. Kansagra and Inwards, {D. J.} and Ansell, {Stephen Maxted} and Ivana Micallef and Johnston, {Patrick Bruce} and William Hogan and Markovic, {Svetomir Nenad} and Porrata, {L. F.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1038/bmt.2017.225",
language = "English (US)",
volume = "53",
pages = "146--154",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

AU - Kansagra, A.

AU - Inwards, D. J.

AU - Ansell, Stephen Maxted

AU - Micallef, Ivana

AU - Johnston, Patrick Bruce

AU - Hogan, William

AU - Markovic, Svetomir Nenad

AU - Porrata, L. F.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of < 3/40.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.

AB - The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of < 3/40.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.

UR - http://www.scopus.com/inward/record.url?scp=85041545981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041545981&partnerID=8YFLogxK

U2 - 10.1038/bmt.2017.225

DO - 10.1038/bmt.2017.225

M3 - Article

C2 - 29035394

AN - SCOPUS:85041545981

VL - 53

SP - 146

EP - 154

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -